Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
Appointed director
Inv. presentation

MERRIMACK PHARMACEUTICALS INC (MACK) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 SC 13D/A Western Standard LLC reports a 13.9% stake in Merrimack Pharmaceuticals, Inc.
08/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Merrimack Reports Second Quarter 2023 Financial Results"
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
06/07/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/04/2023 8-K Quarterly results
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/21/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/21/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Merrimack Reports Full Year 2022 Financial Results"
03/09/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A Point72 Asset Management, L.P. reports a 0% stake in Merrimack Pharmaceuticals, Inc.
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
12/05/2022 8-K Quarterly results
11/30/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
11/09/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
08/04/2022 8-K Quarterly results
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/04/2022 SC 13G Point72 Asset Management, L.P. reports a 6.7% stake in Merrimack Pharmaceuticals, Inc.
08/03/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
05/05/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/27/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Amendment to Amendend and Restated Bylaws of the Registrant"
04/27/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/09/2022 8-K Quarterly results
03/09/2022 10-K Annual Report for the period ended December 31, 2021
02/14/2022 SC 13G/A 22NW, LP reports a 9.3% stake in Merrimack Pharmaceuticals, Inc.
02/14/2022 SC 13G/A Nantahala Capital Management, LLC reports a 4.3% stake in Merrimack Pharmaceuticals, Inc.
11/04/2021 10-Q Quarterly Report for the period ended September 30, 2021
08/05/2021 8-K Quarterly results
08/05/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Merrimack Reports Second Quarter 2021 Financial Results"
08/05/2021 10-Q Quarterly Report for the period ended June 30, 2021
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy